References

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients

10.1182/bloodadvances.2021004467 · 2021 · External reference

Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

10.2967/jnumed.117.193946 · 2018 · External reference

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial

10.1200/jco.2017.76.8093 · 2018 · External reference

Interim PET evaluation in diffuse large B-cell lymphoma employing published recommendations: comparison of the Deauville 5-point scale and the ΔSUVmax method

10.2967/jnumed.120.244145 · 2021 · External reference

Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis

10.2967/jnumed.107.042093 · 2007 · External reference

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

10.1182/blood-2014-03-563627 · 2014 · External reference

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

10.1200/jco.2010.28.1618 · 2010 · External reference

ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

10.1200/jco.1994.12.6.1169 · 1994 · External reference

Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction

10.1016/j.cell.2019.06.011 · 2019 · External reference

Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma

10.1200/jco.2018.78.5246 · 2018 · External reference

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

10.1016/s1470-2045(21)00375-2 · 2021 · External reference

Long-term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL)

10.1182/blood-2021-148078 · 2021 · External reference

Survival with axicabtagene ciloleucel in large B-cell lymphoma

10.1056/nejmoa2301665 · 2023 · External reference

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

10.1056/nejmoa2206913 · 2022 · External reference

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

10.1200/jco.22.01725 · 2023 · External reference

Early positron emission tomography response-adapted treatment in localized diffuse large B-cell lymphoma (aaIPI=0): results of the phase 3 LYSA LNH 09-1B trial

10.1002/hon.5_2879 · 2021 · External reference

Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial

10.1002/cac2.12462 · 2023 · External reference

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

10.1200/jco.2013.53.9593 · 2014 · External reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

10.1056/nejm199512073332305 · 1995 · External reference

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma

10.1200/jco.2008.17.3328 · 2009 · External reference

Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry

10.1200/jco.2010.30.2596 · 2011 · External reference

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

10.1016/s1470-2045(14)70161-5 · 2014 · External reference

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

10.1111/bjh.14046 · 2016 · External reference